AVITA Medical, Inc. (ASX:AVH)
Australia flag Australia · Delayed Price · Currency is AUD
3.070
-0.080 (-2.54%)
Feb 21, 2025, 4:10 PM AEST

AVITA Medical Company Description

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.

The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.

It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.

In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix.

It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020.

AVITA Medical, Inc. is headquartered in Valencia, California.

AVITA Medical, Inc.
AVITA Medical logo
Country United States
Founded 2020
Industry Medical Devices
Sector Healthcare
Employees 260
CEO James Corbett

Contact Details

Address:
28159 Avenue Stanford
Valencia, Delaware 91355
United States
Phone 661 367 9170
Website avitamedical.com

Stock Details

Ticker Symbol AVH
Exchange Australian Securities Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number AU000000AVH4
SIC Code 2836

Key Executives

Name Position
James M. Corbett Chief Executive Officer, President and Executive Director
David O'Toole Chief Financial Officer
David Fencil Senior Vice President of Global Operations
Dr. Katie Bush Ph.D. Senior Vice President of Scientific and Medical Affairs
Debbie Garner Senior Vice President of Global Marketing and Strategy
Rob Hall Senior Vice President of Human Resources
Dr. Niraj Doshi J.D., P.M.P., Ph.D. Senior Vice President of Product Development and Program Management
Ron Lagerquist Senior Vice President of Quality Assurance and Regulatory Affairs
Robin VanDenburgh Senior Vice President of U.S. Commercial Sales